Molbio Diagnostics, an innovative point-of-care (POC) diagnostics company, and UE LifeSciences, a Philadelphia-based innovator engaged in the business of developing and manufacturing health technology solutions, with a primary focus on enabling early cancer detection technologies, announce an exclusive collaboration, seeking to make early breast cancer detection accessible to millions of women in over 50 countries across the developing world.
Through this collaboration, Molbio will bring UE LifeSciences’ iBreastExam —a radiation-free, painless, and FDA-cleared screening device across India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam. Together, they aim to address the late detection of breast cancer, a leading cause of preventable breast cancer mortality. Molbio Diagnostics will leverage its global distribution network and expertise in expanding access to healthcare solutions to promote, market, sell, and distribute the iBreastExam to public and private healthcare providers in these regions.
The iBreastExam is a US Food and Drug Administration-cleared point-of-care, ultraportable, battery-operated device which can enable screening in primary healthcare settings and mass public health campaigns. The device enables primary care providers to identify breast lumps in just minutes without pain, radiation, or complex infrastructure. Using advanced sensor technology, it automates and enhances physical breast examination without requiring interpretation by the user. Ultra portable and easy to operate, iBreastExam brings early detection directly to women in their communities, overcoming barriers to mammogram access in low-resource settings. Secure cloud storage ensures seamless patient follow-up, helping save lives through timely diagnosis and care.
Mihir Shah, founder and CEO of UE LifeSciences, stated, “Our collaboration with Molbio Diagnostics is an important step towards improving access to early breast health screening, particularly in areas where access to screening remains a challenge” He added, “Molbio’s experienced team and market reach can help amplify our mission to transform women’s health and save lives through accessible and innovative early detection.”
Breast cancer is the leading cancer in women, occurring frequently and contributing to the high number of cancer incidences and mortality rates.
Molbio Diagnostics Limited is an innovative point-of-care diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases.
UE LifeSciences is an award-winning women’s health company making early detection of leading cancers in women, equitable and accessible globally. |